# OnCo record notable-trial (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/notable-trial/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "notable-trial", "NCT02395016" ;
  schema:name "NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)"@en ;
  schema:description "In the minority of pancreatic cancers without a KRAS mutation, adding the EGFR antibody nimotuzumab to gemcitabine helped people live longer, and China approved it in 2023."@en ;
  schema:url <https://onco.cc/trials/notable-trial/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02395016>, <https://doi.org/10.1200/JCO.22.02630> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2015-04" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/kras-wild-type-pdac/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/nimotuzumab/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-qin-j-clin-oncol/> .